Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment–real world outcomes J Talbot, R Stuckey, L Crawford, S Weatherby, S Mullin The Journal of Headache and Pain 22, 1-10, 2021 | 47 | 2021 |
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study R Ornello, C Baraldi, S Guerzoni, G Lambru, AP Andreou, B Raffaelli, ... The Journal of Headache and Pain 23 (1), 38, 2022 | 27 | 2022 |
Gender differences in 3-month outcomes of Erenumab treatment—study on efficacy and safety of treatment with Erenumab in men R Ornello, C Baraldi, S Guerzoni, G Lambru, M Fuccaro, B Raffaelli, ... Frontiers in Neurology 12, 774341, 2021 | 18 | 2021 |
Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients S Bhattacharjee, JG Talbot, P Vijayashankar Parkinsonism & Related Disorders 34, 69-70, 2017 | 6 | 2017 |
Moyamoya and progressive myoclonic epilepsy secondary to CLN6 bi-allelic mutations–A previously unreported association J Talbot, P Singh, C Puvirajasinghe, SM Sisodiya, F Rugg-Gunn, ... Epilepsy & Behavior Reports 14, 100389, 2020 | 5 | 2020 |
Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab J Talbot, R Stuckey, N Wood, A Gordon, G Crossingham, S Weatherby European Journal of Hospital Pharmacy, 2024 | 3 | 2024 |
Changing epidemiology in spontaneous bacterial peritonitis and challenging balance between new strategies in empirical antibiotics and emergence of resistant bacteria YH Lim, K Bennett, J Talbot, J Yeh, JG Acevedo AME Medical Journal 3 (3), 2018 | 2 | 2018 |
Can Smoking Status, Exercise Tolerance Or Fev1 Predict 28-Day Readmission Rates In Exacerbations Of Chronic Obstructive Pulmonary Disease (COPD)? JB Morjaria, J Talbot, R Dickinson D108. Pneumonia Epidemiology and Outcomes, A6515-A6515, 2014 | 1 | 2014 |
010 Trigeminal neuralgia in diffuse scleroderma–a rare but recognised association J Talbot, R Patel, J Gormley Journal of Neurology, Neurosurgery & Psychiatry 93 (9), e2, 2022 | | 2022 |
PO001 Successful neurology trainee research network collaborative audit E Abdelgadir, D Patel, M O’Gara, O Leach, O Al Masri, S Bhattacharjee, ... Journal of Neurology, Neurosurgery & Psychiatry 88 (Suppl 1), A13-A13, 2017 | | 2017 |
PO213 Sonar identifies research training needs in a clinical training program E Abdelgadir, D Patel, M O’Gara, O Leach, O Al Masri, S Bhattacharjee, ... Journal of Neurology, Neurosurgery & Psychiatry 88 (Suppl 1), A68-A68, 2017 | | 2017 |
SONAR identifies registrar research training needs in a clinical training program E Abdelgadir, O Almasri, S Bhattacharjee, O Leach, M O'gara, D Patel, ... | | 2017 |
Does having previous sputum results improve rationalisation of antimicrobial prescribing during acute exacerbations of COPD? R Dickinson, J Talbot, J Thompson, H Cummings, J Morjaria European Respiratory Journal 44 (Suppl 58), 2014 | | 2014 |
Does sputum, biochemical and radiological markers of infection correlate with antibiotic prescribing in acute exacerbations of COPD? J Talbot, R Dickinson, J Thompson, K Thompson, J Morjaria European Respiratory Journal 44 (Suppl 58), 2014 | | 2014 |
D108 PNEUMONIA EPIDEMIOLOGY AND OUTCOMES: Can Smoking Status, Exercise Tolerance Or Fev1 Predict 28-Day Readmission Rates In Exacerbations Of Chronic Obstructive Pulmonary … JB Morjaria, J Talbot, R Dickinson American Journal of Respiratory and Critical Care Medicine 189, 1, 2014 | | 2014 |
Switching anti-CGRP monoclonal antibodies in chronic migraine J Talbot, R Stuckey, N Wood, A Gordon, G Crossingham, S Weatherby | | |